Avalo Therapeutics
AVTX

$7.56

1.82%

Market Cap: $7.82M

About: Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 19

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

52% more capital invested

Capital invested by funds: $1.9M [Q1] → $2.89M (+$994K) [Q2]

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

11.58% more ownership

Funds ownership: 10.94% [Q1] → 22.53% (+11.58%) [Q2]

11% more funds holding

Funds holding: 18 [Q1] → 20 (+2) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for AVTX.

See Analyst Rankings

Financial journalist opinion

The 3 Best Personalized Nutrition Stocks to Buy Now

It could be quite beneficial to invest in personalized nutrition stocks for this month in July. Some applications in the personalized nutrition market are now using artificial intelligence and machine learning, or ML, to provide consumers with more targeted and therefore better advice on their diet.

The 3 Best Personalized Nutrition Stocks to Buy Now

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer.

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS) is now active, permitting the Company to commence its Phase 2 (LOTUS) clinical trial in patients with HS. Avalo expects to enroll the first patient in its Phase 2 LOTUS Trial this year.

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer.

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel being held at 11:45 AM ET on June 24, 2024 at the Oppenheimer Novel Targets in Immunology Summit in New York, NY.

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Zacks Investment Research

Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?

Here is how Avalo Therapeutics, Inc. (AVTX) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.

Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024.

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Zacks Investment Research

Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why

Avalo (AVTX) surges on adding a new pipeline drug, which has its origins at Eli Lilly. Alongside the acquisition, it also secured funding to continue operations beyond 2027.

Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of $16.60.

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

See News Rankings